Structure and function of A41, a vaccinia virus chemokine binding protein by Bahar, MW et al.
Structure and Function of A41, a Vaccinia
Virus Chemokine Binding Protein
Mohammad W. Bahar
1[
, Julia C. Kenyon
2[
, Mike M. Putz
2[
, Nicola G. A. Abrescia
1
, James E. Pease
3
, Emma L. Wise
3
,
David I. Stuart
1
, Geoffrey L. Smith
2*
, Jonathan M. Grimes
1*
1 The Division of Structural Biology and The Oxford Protein Production Facility, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom,
2 Department of Virology, Faculty of Medicine, Imperial College London, St. Mary’s Campus, London, United Kingdom, 3 Leukocyte Biology Section, NHLI Division, Faculty of
Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington Campus, London, United Kingdom
The vaccinia virus (VACV) A41L gene encodes a secreted 30 kDa glycoprotein that is nonessential for virus replication
but affects the host response to infection. The A41 protein shares sequence similarity with another VACV protein that
binds CC chemokines (called vCKBP, or viral CC chemokine inhibitor, vCCI), and strains of VACV lacking the A41L gene
induced stronger CD8þ T-cell responses than control viruses expressing A41. Using surface plasmon resonance, we
screened 39 human and murine chemokines and identified CCL21, CCL25, CCL26 and CCL28 as A41 ligands, with Kds of
between 8 nM and 118 nM. Nonetheless, A41 was ineffective at inhibiting chemotaxis induced by these chemokines,
indicating it did not block the interaction of these chemokines with their receptors. However the interaction of A41 and
chemokines was inhibited in a dose-dependent manner by heparin, suggesting that A41 and heparin bind to
overlapping sites on these chemokines. To better understand the mechanism of action of A41 its crystal structure was
solved to 1.9 A˚ resolution. The protein has a globular b sandwich structure similar to that of the poxvirus vCCI family of
proteins, but there are notable structural differences, particularly in surface loops and electrostatic charge distribution.
Structural modelling suggests that the binding paradigm as defined for the vCCI–chemokine interaction is likely to be
conserved between A41 and its chemokine partners. Additionally, sequence analysis of chemokines binding to A41
identified a signature for A41 binding. The biological and structural data suggest that A41 functions by forming
moderately strong (nM) interactions with certain chemokines, sufficient to interfere with chemokine-glycosaminogly-
can interactions at the cell surface (lM–nM) and thereby to destroy the chemokine concentration gradient, but not
strong enough to disrupt the (pM) chemokine–chemokine receptor interactions.
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Introduction
Chemokines (chemotactic cytokines) comprise a large
family of small (; 7–14 kDa), secreted proteins that direct
the migration of leukocytes into areas of infection and
inﬂammation, as part of the innate immune response [1,2].
They function by binding to cell surface glycosaminoglycans
(GAGs) and establishing concentration gradients, which are
detected by their cognate seven-transmembrane G-protein
coupled receptors (GPCRs) on the surface of immune cells.
This leads to activation of leukocytes and macrophages and
their consequent chemotaxis to sites of inﬂammation and
infection. Chemokines are classiﬁed into four subfamilies
called C, CC, CXC and CX3C based on the arrangement of
conserved disulphide forming cysteine residues at the N
terminus [3]. Despite differences in primary sequence and
varied functions within the superfamily, chemokines adopt
very similar tertiary structures, with an extended N-terminal
loop region followed by a three b stranded sheet arranged in
a Greek key motif [4,5], and form strong pM interactions with
their cognate receptors.
Poxviruses are a family of large, double-stranded DNA
viruses that replicate in the cell cytoplasm [6]. Vaccinia virus
(VACV), the prototype member of this family, was the live
vaccine used to eradicate smallpox, caused by variola virus
(VARV) [7]. The VACV strain Copenhagen genome contains
approximately 200 genes [8], although the number of genes
varies slightly between strains [9]. About half of these genes
are dispensable for virus replication but affect virus
virulence, host range or interactions with the immune system.
One poxvirus immune evasion strategy is to target the
chemokine/chemokine receptor system by encoding viral
mimics of chemokines or chemokine receptors, or to express
secreted chemokine binding proteins [10,11]. Several poxvi-
ruses encode a secreted CC chemokine inhibitor (vCCI) (also
previously called vCKBP/T1/35 kDa) that is unrelated to
cellular chemokine receptors and binds tightly to CC
chemokines with pM afﬁnities [12–14]. vCCI functions by
competing for and preventing the interaction of chemokines
with their receptors on leukocytes and so blocking their role
in the inﬂammatory response. In contrast, it was proposed
that another poxvirus chemokine binding protein, called M-
T7 from myxoma virus (MYXV), blocks the binding of
chemokines to GAGs and thereby prevents the interaction
of the chemokines with the endothelial cell surface [15].
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Consequently, a chemokine concentration gradient is not
established near the site of infection and leukocytes are not
recruited.
The vCCI proteins from leporipoxviruses and orthopoxvi-
ruses share several conserved features and therefore might
share similar binding modes with chemokines. A collection of
structures of vCCI proteins from cowpox virus (CPXV) [16],
rabbitpox virus (RPXV) [17] and ectromelia virus (ECTV) [18]
reveal a distinct b sandwich topology with no obvious
relationship to host chemokine receptors, which are seven-
transmembrane GPCRs. One face of the vCCI b sandwich
(sheet I) is rather ﬂat and electrostatically bland, whereas the
second face (sheet II) is elaborated by a conserved loop, that
contributes to the highly negatively charged solvent acces-
sible surface. The acidic surface residues of sheet II are highly
conserved in vCCI proteins and were hypothesized to be the
chemokine-binding surface for these proteins [16]. A sub-
sequent structure of the complex between RPXV vCCI and
human CCL4 conﬁrmed this [17], and structure-based muta-
tional analysis of the ECTV vCCI protein highlighted residues
involved in high-afﬁnity interactions between vCCIs and their
CC chemokine partners [18]. These recent structures have
contributed to an emerging paradigm for vCCI–chemokine
interactions, allowing comparisons to be made of the binding
modes of these soluble viral proteins and host chemokine
receptors.
This paper focuses on another immunomodulatory protein
that shares sequence similarity to vCCI and is encoded by
VACV gene A41L. This gene has also been called 166 using a
nomenclature in which genes are numbered sequentially
from left to right of the VACV strain Western Reserve (WR)
[9]. The A41 protein from VACV strain WR is a secreted 30
kDa glycoprotein and very similar proteins are expressed by
camelpox virus, CPXV and all 16 strains of VACV tested [19].
In addition, genome sequencing showed that all orthopoxvi-
rus species and strains studied (over 70 in total) encode a
highly conserved A41L gene [9]. VACV A41 blocks the
recruitment of cells to the site of VACV infection in a rabbit
intradermal model, and decreases immunopathology and
viral clearance in a mouse intranasal model [19]. When gene
A41L was deleted from modiﬁed VACV Ankara (MVA), an
attenuated VACV strain, the resultant virus induced a
stronger CD8þ T-cell response and conferred better protec-
tion against subsequent challenge with a pathogenic strain of
VACV [20]. Although A41 has biological properties consistent
with those of chemokine binding proteins and is related to a
known chemokine binding protein, hitherto, the ligands for
A41 were unknown.
A41 has limited sequence similarity to the poxvirus vCCI
family of proteins (;19% sequence identity and ;40%
conservation to both CPXV and ECTV vCCIs) and in addition
shares a similar hydropathy proﬁle and has conserved
cysteine residues [19]. A41 also shares amino acid similarity
with orf virus GIF protein, another member of the vCCI
protein family, which binds granulocyte macrophage colony
stimulating factor (GM-CSF) and interleukin (IL)-2 [21].
Although many poxviruses encode proteins related to VACV
vCCI, there are no close relatives outside poxviruses and so
the origin of this gene family is uncertain. VACV and orf
virus genomes have quite different GþC content (33% for
VACV and 64% for orf virus) and the GþC contents of the
VACV gene A41L and the orf virus gene encoding the GIF
protein match that of the parent virus. Therefore, these genes
have been present in these genomes for a long time, or, less
likely, were acquired recently from an unknown source with
similar GþC content.
To better understand the function of VACV A41 we have
identiﬁed several chemokines as binding partners and solved
the A41 crystal structure and reﬁned it to a Bragg spacing of
1.9 A˚. To identify ligands for A41, we expressed and puriﬁed
it from a VACV-expression system [22] in mammalian cells
and screened a panel of chemokines for binding by surface
plasmon resonance. A41 bound to CCL25, CCL26, CCL28 and
CCL21 with a Kd between 10
7 to 109 M. A41 did not inhibit
chemokine-induced chemotaxis, although the interaction
between A41 and chemokines was inhibited by GAGs,
suggesting A41 functions by blocking the binding of chemo-
kines to GAGs. The A41 structure reveals the b sandwich fold
observed in the vCCI family of proteins. However, there are
notable differences between the structure of A41 and the
vCCIs of CPXV [16], RPXV [17] and ECTV [18], notably in the
conserved surface loop and the surface charge distribution.
In light of the biochemical and structural data we propose a
model for the biological function of A41 and the structural
interactions that underpin it.
Results
A41 is secreted from infected cells and has a primary amino
acid sequence related to the vCCI family of poxvirus proteins
that bind chemokines. However, the ligand(s) for A41 is (are)
unknown. To investigate the mechanism of action of A41, we
searched for ligands using A41 expressed from mammalian
cells using the VOTE expression system from VACV [22]. A
recombinant virus (VOTE-A41) was constructed in which the
A41L gene was driven from an IPTG-inducible bacteriophage
T7 RNA polymerase promoter (see Materials and Methods).
Cells were infected with VOTE-A41 and expression of A41
was induced by addition with IPTG. A41 was collected from
the supernatant of infected cells and puriﬁed by ion exchange
and size exclusion chromatography (SEC) (Materials and
Methods). The ﬁnal preparation was analysed by SDS-PAGE
and contained a single protein of 30 kDa that reacted with an
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Author Summary
As part of the innate immune response (for example to virus
infection), the body produces proteins called chemokines, which act
by directing white blood cells (leukocytes) to the areas of infection
and inflammation. Viruses have evolved mechanisms to fight this
immune response. Indeed, so important is this need to protect
themselves from the immune system that some viruses, such as
poxviruses, devote up to half their genetic information to this battle.
We have studied a protein called A41, one component of the
response of vaccinia virus (the vaccine used to eradicate smallpox)
to the immune system and shown that it interferes with the function
of a group of chemokines. These chemokines function by forming
concentration gradients along which the white blood cells migrate,
and A41 sequesters the chemokines, thereby preventing formation
of the gradient. Interestingly, we show also that A41 is very similar in
structure to another group of proteins, called vCCIs, that bind
chemokines more tightly, blocking their attachment to white blood
cells, suggesting that both mechanisms are important for virus
virulence.
anti-A41 polyclonal antibody [19] by immunoblotting (data
not shown).
A41 Binds to a Subset of CC Chemokines
A41 was coupled to the surface of a CM5 sensor chip and 39
murine and human chemokines (murine chemokines CCL1,
CCL2, CCL4, CCL6, CCL7, CCL8, CCL9/10, CCL11, CCL12,
CCL19, CCL20, CCL21, CCL22, CCL24, CCL27, CCL28,
CXCL2, CXCL5, CXCL9, CXCL10, CXCL11, CXCL12a,
CXCL12b, CXCL13, XCL1, CX3CL1, and human chemokines
CCL14, CCL15, CCL16, CCL17, CCL18, CCL23, CCL25,
CCL26, CXCL3, CXCL4, CXCL6 and CXCL7) were passed
sequentially across the chip surface and binding was analysed
by surface plasmon resonance (BIACORE). Where possible,
mouse chemokines were used initially because VACV strains
WR and MVA lacking the A41L gene showed a distinct
biological phenotype, compared to control viruses, in a
mouse model of infection. A control surface coated with
ovalbumin (45 kDa, pI 4.5), vCCI (as a positive control for CC
chemokines) and a blank surface were analysed in parallel
channels on the same chip. The sensorgram for the blank
surface was subtracted from that for each protein. Both the
chemokines and the immobilised proteins differed in mass
and so the binding responses recorded at the end of the
injection (RUeq) were converted into %Rmax (where Rmax is
the calculated binding capacity). Table 1 shows the binding
activity of immobilised A41 and ovalbumin for the different
chemokines expressed as %Rmax. Binding of all chemokines
to ovalbumin and the majority of chemokines to A41 were
very low (,10% Rmax), but binding to A41 of. 20% Rmax was
observed for hCCL26, hCCL25, mCCL28, hCXCL4, mCCL21
and mCXCL13 (Table 1), suggesting that these might be
ligands for A41. vCCI also bound all the CC chemokines
bound by A41.
To investigate these interactions further, kinetic analyses
were performed for mouse and human versions of these
chemokines using A41 produced from mammalian cells and
from E. coli. Binding afﬁnities (Kd) to A41VOTE and A41E. coli
(mean values from at least two experiments performed on
two different chips) are listed in Table 2. Kd values of mouse
and human CCL25, CCL28, CCL26 and CCL21 are in the
range of 8–118 nM, whereas Kd values for hCXCL4, hCXCL13
Table 1. Chemokine Binding (%Rmax) to A41 and Ova Detected by Surface Plasmon Resonance
Chemokine Colloquial Name Mass (kDa) %Rmax (A41) %Rmax (Ova)
hCCL1 I-309 8.5 3.3 0
mCCL2 JE 13.8 4.0 0
mCCL4 MIP-1b 7.8 0 0
mCCL6 C10 10.7 0 0
mCCL7 MCP-3 8.5 6.2 0
mCCL8 MCP-2 8.5 0 0
mCCL9/10 MIP-1c 11.6 0.3 0
mCCL11 Eotaxin 8.4 12.2 0
mCCL12 MCP-5 9.3 1 0
hCCL14 HCC-1 8.4 0 0
hCCL15 MIP-5 10.1 0 0
hCCL16 LEC 11.2 0.9 0
hCCL17 TARC 8.0 2.3 0
hCCL18 MIP-4 7.8 4.1 0
mCCL19 MIP-3b 9.2 0 0
mCCL20 MIP-3a 7.9 6.5 0
mCCL21 Exodus-2 12.0 20.9 2.8
mCCL22 MDC 7.8 1.1 0
hCCL23 MIP-3 11.3 0 0.6
mCCL24 Eotaxin-2 10.3 12.6 8.0
hCCL25 TECK 14.2 40.2 8.5
hCCL26 Eotaxin-3 8.4 55.0 4.4
mCCL27 CTACK 10.9 15.7 2.1
mCCL28 MEC 12.6 29.9 3.2
mCXCL2 MIP-2 7.8 0 0
hCXCL3 GROc 7.9 0 0
hCXCL4 PF-4 7.8 36.6 4.9
mCXCL5 LIX 9.8 0.1 0
hCXCL6 GCP-2 7.9 8.7 0
hCXCL7 NAP-2 7.6 0 0
mCXCL9 MIG 12.2 13.2 0
mCXCL10 IP-10 8.5 10.0 0.2
mCXCL11 I-TAC 9.0 12.4 5.1
mCXCL12a SDF-1a 7.9 0 0
mCXCL12b SDF-1b 8.5 6.8 0.3
mCXCL13 BCA-1 9.8 20.6 4.5
mCXCL16 SR-PSOX 9.9 0 0
hCX3CL1 Fractalkine 8.5 2.2 0
mXCL1 Lymphotactin 10.0 16.2 1.2
doi:10.1371/journal.ppat.0040005.t001
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and mXCL1 were higher than 1 lM. Although there were
some differences, the binding afﬁnities for each chemokine
were generally similar for A41VOTE and A41E. coli, indicating
that A41 can bind to these ligands whether or not it is
glycosylated. Overall the Kd values of A41 for these human
and mouse chemokines are one to three orders of magnitude
higher (lower afﬁnity) than the Kd values of vCCI for many CC
chemokines [13].
Poxvirus chemokine binding proteins have been reported
to interact with chemokines in two distinct ways. The vCCI
protein encoded by VACV and CPXV binds to chemokines
such that receptor binding is blocked [13,14,17,23,24] and, the
vCCI-chemokine interaction was not inhibited by high
concentrations of GAGs, such as heparin [13]. In contrast,
the binding of MYXV M-T7 protein to chemokines was
blocked by endothelial cell associated GAGs [15]. On this
basis a model of the chemokine binding was proposed in
which the chemokine receptor binding site and the GAG
binding site were considered distinct. The binding of vCCI to
CC chemokines would block receptor binding, whereas the
inhibition of GAG-chemokine interaction by M-T7 would
prevent the establishment of a chemokine concentration
gradient around sites of inﬂammation and the consequent,
recruitment of leukocytes. Blocking the binding of a chemo-
kine to its receptor will inhibit leukocyte chemotaxis in vitro,
whereas blocking binding of a chemokine to GAGs will not.
This distinction was exploited to investigate the mechanism
of interaction of A41 with chemokines.
A41 Does Not Inhibit Chemokine-Induced Leukocyte
Chemotaxis
The ability of A41 to inhibit chemotaxis induced by CCL21,
CCL25, CCL26 and CCL28 was examined. Murine L1.2 cells
expressing endogenous CCR7 were used to examine human
and mouse CCL21-induced chemotaxis; 4DE4 cells expressing
CCR3 stably were used to examine human CCL26-induced
chemotaxis; and murine L1.2 cells were transfected with
plasmids encoding wild type or HA-tagged human CCR9 and
CCR10 to examine human and mouse CCL25- and CCL28-
induced chemotaxis [25]. In pilot experiments, cells trans-
fected with the HA-tagged CCR9 and CCR10 migrated in
response to CCL25 and CCL28 at similar levels to cells
transfected with the wild type receptors (data not shown).
Thereafter, the HA-tagged versions were used so that cell-
surface receptor expression could be veriﬁed by FACS using
an anti-HA antibody before chemotaxis experiments (data
not shown). The concentration of each chemokine that
induced optimal chemotaxis of the appropriate cell type
was determined and this concentration was used to deter-
mine whether A41 can block chemotaxis. A41VOTE, A41E. coli
or ovalbumin were incubated at various molar ratios (up to
200:1) with each chemokine and the number of cells that
migrated through a membrane in response to this mixture
was determined (Figure 1).
No inhibition of chemotaxis was observed with murine and
human CCL21 (Figure 1). Similarly, with murine and human
CCL25 and hCCL26, even a 200-fold excess of A41 was unable
to inhibit chemotaxis by 50% compared to chemokine alone
(Figure 1). Only with human and murine CCL28 was A41 able
to reduce chemotaxis to ;10% of levels induced by chemo-
kine alone, but in the latter case chemotaxis was also
inhibited ;65% by a similar molar excess of ovalbumin.
Moreover, a 50-fold excess of mCCL28 inhibited chemotaxis
by only;35% (Figure 1) and this is inconsistent with efﬁcient
blockade of chemokine–chemokine receptor interaction.
Collectively, these data indicate that A41 is unable to block
chemokine-induced leukocyte chemotaxis effectively. These
results are consistent with the weaker binding of A41 to
chemokines, compared to the binding of those chemokines to
their cellular receptors, and contrast with results for VACV
vCCI that inhibited chemotaxis efﬁciently in a dose-depend-
ent manner and at much lower molar concentrations [13].
A41 Binding Blocks the Chemokine GAG-Binding Domain
The failure of A41 to inhibit chemokine-induced chemo-
taxis and the Kd values for its interaction with chemokines
(Table 2), suggest that A41 might function by blocking the
interaction of chemokines with GAGs. This was investigated
by immobilising A41 on a sensor chip, passing hCCL28 across
the chip alone or in the presence of increasing concen-
trations of heparin (sodium salt, MW 4,000–6,000) and
measuring hCCL28 binding by BIACORE. The interaction
of A41 and hCCL28 was inhibited in a dose-dependent
manner and complete inhibition was achieved with 500 ng/ml
heparin (Figure 2A). Similarly, heparin inhibited the binding
of hCCL21, hCCL25, hCCL26 and hCCL28 to immobilised
Table 2. Kinetic Parameters and Affinities of Mouse and Human Chemokines for A41
Chemokine A41 VOTE A41 E. coli
ka (M
1s1) kd (s
1) Kd (nM) (range, n) ka (M
1s1) kd (s
1) Kd (nM) (range, n)
mCCL25 1.10 3 106 3.33 3 102 30.3 (28–32, 3) n.d.
hCCL25 1.44 3 106 3.56 3 102 24.7 (16–41, 6) 1.51 3 106 1.20 3 102 7.95 (5–12, 3)
hCCL26 1.22 3 106 8.66 3 102 71.0 (23–179, 3) 1.32 3 105 1.15 3 102 87.2 (22–345, 2)
mCCL28 5.03 3 105 4.53 3 102 90.0 (73–114, 4) n.d.
hCCL28 8.44 3 105 5.02 3 102 59.5 (41–86, 2) 1.56 3 106 5.53 3 102 35.5 (30–42, 2)
mCCL21 4.48 3 105 5.28 3 102 118 (51–263, 6) 7.81 3 105 1.95 3 102 25.0 (22–28, 2)
hCCL21 4.14 3 105 4.81 3 102 116 (39–280, 3) n.d.
hCXCL4 9.54 3 103 1.96 3 102 2,058 (812–5,214, 2) n.d.
mCXCL13 8.14 3 103 1.73 3 102 2,129 (839–12,896, 3) n.d.
mXCL1 7.91 3 102 9.58 3 102 12,119 (5,318–27,621, 2) n.d.
n.d., not determined.
doi:10.1371/journal.ppat.0040005.t002
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A41 in a dose-dependent manner when A41 was produced in
either mammalian cells (Figure 2B) or E. coli (Figure 2C). The
concentration of heparin used to achieve 50% inhibition was
;100 ng/ml (;20 nM) and this was lower than used by other
investigators to achieve disruption of the M-T7 chemokine
binding protein from MYXV with RANTES [15] or the
Figure 2. Inhibition of Binding of Chemokines to A41 in the Presence of
Heparin Sodium Salt
(A) A41VOTE was immobilised on a sensor chip and increasing
concentrations (0, 31.25, 62.5, 125, 250, 500 ng/ml) of heparin sodium
salt (low molecular weight, MW 4,000–6,000, Sigma) were mixed with
hCCL28 and passed across the sensor chip. Chemokine binding to A41 is
shown by sensorgrams expressed as RU. (B,C). Heparin inhibits binding
of human CCL21, CCL25, CCL26 and CCL28 to A41VOTE (B) and A41E. coli
(C) (filled symbols depict activity with chemokine only). (D) Binding of
human CCL25 to A41VOTE in the presence of various sulphated GAGs
(heparin, heparan sulphate [heparan s], chondroitin sulphate B [chond s
Figure 1. A41 Does Not Inhibit Leukocyte Chemotaxis Induced by
Human or Murine CCL21, CCL25, CCL26 and CCL28
A chemokine was incubated with A41 (grey bars) or ovalbumin (open
bars) at the indicated molar excess in the bottom of a well of a 96-well
chemotaxis plate and 2 3 105 cells were placed in the upper chamber.
The plate was incubated for 5 h and the number of cells that had
migrated through the membrane was determined. Data are expressed as
a percentage of the number of cells that migrated in response to
chemokine alone, following subtraction of migration in buffer only, and
the error bars represent the S.E.M. based on five or more samples. The
number of cells migrating in the absence of chemokine was below 3%.
doi:10.1371/journal.ppat.0040005.g001
B, ¼ dermatan], chondroitin sulphate C [chond s C], hyaluronic acid
[hyalur ac] and dextran sulphate [dextran s]) at 125 ng/ml (grey bars) and
250 ng/ml (white bars). Data are expressed as the percentage binding
compared to CCL25 alone.
doi:10.1371/journal.ppat.0040005.g002
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interaction of chemokines with the endothelial cell surface
[26]. Apart from heparin, other sulphated GAGs were also
tested for their ability to inhibit binding of chemokines to
A41. Heparin and dextran sulphate inhibited the hCCL25-
A41 interaction, but heparan sulphate, chondroitin sulphate
B, chondroitin sulphate C and hyaluronic acid did not (Figure
2D). Similar results were obtained with A41 produced from E.
coli or mammalian cells and with hCCL21, hCCL26 and
hCCL28 (data not shown). Notably each GAG able to inhibit
the hCCL25-A41 interaction was more highly charged than
those that did not inhibit.
Collectively these data show that A41 binds a subset of CC
chemokines (CCL21, CCL25, CCL26 and CCL28) via a site
that overlaps their GAG-binding site, but A41 does not
inhibit leukocyte chemotaxis.
The Structure of A41
To understand the structural basis of the action of A41, its
crystal structure was determined using protein expressed in
E. coli and refolded from inclusion bodies (Materials and
Methods). Phase determination was accomplished by MAD
analysis of Seleno-methione (SeMet)-labelled crystals. Elec-
tron density was observed for residues 26–219 (numbering for
mature protein begins at one) and the structure was reﬁned
to 1.9 A˚ (ﬁnal R ¼ 20.4 and Rfree ¼ 25.2, Table 3). A41 is a
single domain protein with the distinctive b sandwich fold
seen in the vCCI class of poxvirus chemokine binding
proteins. The two b sheets that form the b sandwich, lie
parallel to each other (Figure 3A), and are linked by an array
of large loops. Five anti-parallel b strands (6, 7, 1, 12 and 13)
form b sheet I and deﬁne the core of the structure (the
naming of secondary structure is as deﬁned in Carﬁ et al,
1999). The second b sheet (sheet II) is also composed of 5 b
strands; 2, 4, 5 and 9 are anti-parallel whilst 11 is adjacent to
and parallel with 9. Sheet I is largely buried from solvent by
two long enveloping loops on one side and sheet II on the
other (the other face of sheet II is exposed to solvent). One of
these loops (the 9–11 loop, residues 113–144) wraps around
the molecule and connects b strands 9 and 11 (Figure 3B),
whilst the second comprises the C terminus and packs tightly
against the face of sheet I, and bears strands 14 and 15. Two
short b strands (10 and 14) from these loops clip together in
front of sheet I. There are also two short helical segments, the
ﬁrst of which (a1) packs against the back of sheet II and is
preceded by strand 7. The second, a2, helix comprises a single
turn prior to strand 10. Eight cysteine residues in A41 form
four disulphide bridges (C6-C166, C33-C199, C58-C104, and
C112-C152).
Structural Comparisons between A41 and Poxvirus vCCIs
Despite sharing only 19% sequence identity with CPXV
and ECTV vCCI, the structure of A41 is strikingly similar to
the poxvirus vCCI family of secreted chemokine binding
proteins. Superposition of A41 with the CPXV vCCI [16]
(Figure 3C) aligns 159 Ca atoms (out of 199) with an rmsd of
2.4 A˚. The level of similarity is comparable for the recent
structures of RPXV [17] and ECTV [18] vCCI proteins (2.4 A˚
and 2.5 A˚ rmsds for 159 and 160 residues respectively). In
addition, there is notable structural similarity with the M3
protein of murine cherpesvirus68 (cHV68) [27], which binds
Table 3. Data Collection and Refinement Statistics for A41
SeMet A41 peak SeMet A41 inflection SeMet A41 remote Native A41
Data collection
and processing
X-ray source ESRF BM14 ESRF BM14 ESRF BM14 ID14 EH1
Wavelength (A˚) 0.9792 0.9795 0.9611 0.9310
f 9, f 99 7.63, 5.74 10.36, 3.28 3.00, 3.50
Space group P21 P21 P21 P21
Unit Cell [a, b, c (A˚); b (8)] 36.7, 60.4, 50.6; 91.2 36.7, 60.4, 50.5; 91.2 36.7, 60.4, 50.6; 91.1 36.7, 60.8, 50.5; 91.0
Resolution range (A˚)a 20–2.5 (2.6–2.5) 20–2.5 (2.6–2.5) 20–2.5 (2.6–2.5) 30–1.9 (2.0–1.9)
No. of images 371 180 180 378
Unique Reflections 7,846 7,748 7,749 17,533
Redundancya 6.8 (4.6) 3.8 (3.8) 3.8 (3.7) 7.7 (7.0)
Completeness (%)a 100.0 (100.0) 99.8 (100.0) 99.8 (100.0) 99.9 (99.8)
I/r(I)a 17.1 (3.0) 12.3 (2.7) 11.0 (2.0) 25.7 (2.4)
Rmerge (%)
a,b 10.3 (43) 9.2 (45.2) 9.9 (52.5) 8.0 (87.5)
Refinement statistics Refinement resolutiona 50–1.9 (2.0–1.9)
Number of reflections 15741
Rfactor(%)
a,c 19.4
Rfree(%)
a,d 24.9
Rmsd bonds (A˚) 0.012
Rmsd angles (8) 1.533
Rmsd main chain bond B (A˚2) 2.657
Rmsd side chain bond B (A˚2) 4.653
Number of protein atoms per
asymmetric unit (waters)
1551 (160)
Average protein B factors (waters) (A˚2) 34.4 (37.0)
Rmsd, root-mean-square deviation from ideal geometry.
aValues in parentheses are for the outermost resolution range.
bRmerge ¼ Rhkl RijI(hkl;i) – ,I(hkl).j/Rhkl RiI(hkl;i), where I(hkl;i) is the intensity of an individual measurement and ,I(hkl). is the average intensity from multiple observations.
cRfactor ¼ RhkljjFobsj  kjFcalcjj/RhkljFobsj.
dRfree equals the R factor against 5% of the data removed prior to refinement.
doi:10.1371/journal.ppat.0040005.t003
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all four classes of chemokines. However M3 is larger,
consisting of N- and C-terminal domains, each possessing b
sandwich cores similar to those of the vCCIs. The N- and C-
terminal domains can be superposed on A41 with an rmsd of
2.5 A˚ and 2.8 A˚ respectively (86 and 47 residues equiv-
alenced).
The most signiﬁcant structural deviations between A41 and
the vCCIs occur in certain surface loops. The ﬁrst of these,
the 9–11 loop (A41 residues 113–144) wraps around the
bottom of the b sandwich before arching up the face of sheet
I (Figure 3B). The equivalent loop in the CPXV vCCI (residues
133–161, as deﬁned by the structural alignment) has a
markedly different orientation and wraps over the top half
of sheet I (Figure 3D).
The second major deviation between A41 and the vCCI
proteins lies in the orientation of loops projecting from the
face of sheet II (Figure 3D). The CPXV vCCI protein [16]
contains an extended and highly acidic loop (the 2–4 loop)
between strands 2 and 4 that protrudes from the plane of
sheet II and makes contact with a symmetry related molecule,
giving rise to a crystallographic dimer. This feature is
conserved in the RPXV [17] and ECTV [18] vCCI proteins,
but is absent in A41 (Figure 3B, 3E) and makes a signiﬁcant
contribution to the charge characteristics of sheet II (see
below).
The Surface Properties of A41 and Modelling the A41-
Chemokine Complex
The surface charge properties of A41 are broadly similar to
those seen in other poxvirus vCCI proteins, although sheet I
exhibits a large patch of positive charge (Figure 4A) whereas
in CPXV vCCI sheet I is comparatively uncharged (Figure 4B).
On the opposite face of A41 (sheet II) the dominant
electrostatic feature is a negatively charged patch, and
although this is not conserved in sequence between A41
and the vCCIs this region is negatively charged in the vCCIs
and is conserved within that family (E46, D49, E125 and Y62
in particular, CPXV numbering). The complex of RPXV vCCI
with chemokine CCL4 demonstrated that this negatively
charged surface forms crucial electrostatic interactions with
the positively charged 20s and 40s loop of the chemokine
(Figure 5A, 5B). This charged surface includes the acidic 2–4
loop that harbours residues E46 and D49 and protrudes from
sheet II to lock the chemokine in place. This loop differs in
length in the vCCIs (it is 16 and 27 aa long in CPXV and
RPXV respectively) and is absent in A41. Mapping structure
based sequence alignment between A41 and the vCCIs onto
the surface of A41 reveals that below this unconserved
charged patch is a region of conservation (Figure 6A, 6B),
central to which is a strictly conserved phenylalanine (F181 in
A41) which forms a hydrophobic depression on the edge of
the b sandwich in A41 and the vCCIs (Figure 5D).
To try and understand this pattern of sequence conserva-
tion, we modelled the binding of A41 to its chemokine
binding partners using the structure of RPXV vCCI bound to
CCL4 (pdb code 2ff3). Although only simple rigid body
superpositions were performed to separately position A41
and chemokine hCCL26 (pdb code 1g2s) onto the vCCI-CCL4
complex (maximizing the structural overlap with the appro-
priate component, program SHP [28]), the quality of the ﬁt of
docking is surprisingly good, with few serious steric clashes
(11 residues of CCL26 are within 4 A˚ of 14 residues of A41,
Figure 5C, 5D). This A41-CCL26 model reveals that for A41
both the region of sequence conservation, in particular the
hydrophobic patch around F181, and the negatively charged
patch make close contacts to the chemokine.
Analysis of the RPXV vCCI-CCL4 complex shows that two
regions of the chemokine are important for binding, both of
which show amino acid sequence conservation. The ﬁrst
region is the N-terminal loop of CCL4, in particular a highly
conserved phenylalanine at position 13 in CCL4, which makes
contact with the conserved vCCI residues (homologous to
F181 in A41) at the edge of the b sandwich that forms the
shallow hydrophobic depression. Secondly, positively charged
residues in the 20s and 40s loops of CCL4 (particularly
positions corresponding to 17, 23, 45, 47 and 48 CCL26,
Figure 5E) interact with the negatively charged surface
formed primarily by the 2–4 loop of the vCCI. The molecular
determinants shaping this binding mechanism are highly
conserved in all CC chemokines that bind vCCIs with high
afﬁnity [29].
Although the structure of A41 is largely similar to the
vCCIs, only a subset of CC chemokines bind to A41 with
measurable afﬁnity, and even the tightest interaction is nearly
two orders of magnitude weaker than achieved for by the
VACV vCCI and CCL3. Nevertheless, the critical residues that
deﬁne the binding mode of chemokines to vCCIs are
conserved in the subset of chemokines (CCL21, 25, 26 and
28) that bind to A41 (Figure 5E). The absence of the 2–4 loop
in A41 may explain the speciﬁcity of A41 for certain CC
chemokines and underlies the weakness of the interaction.
This loop is likely to be important for the broad speciﬁcity of
the vCCI proteins, providing a somewhat ﬂexible electrostatic
platform with which to sequester chemokines via their
positively charged GAG-binding sites. High afﬁnity might
then be conferred by hydrophobic interactions of the N-
terminal loop. The lack of the 2–4 loop may therefore restrict
the selectivity of A41 to only a few chemokines, although the
conservation of a negative surface patch on sheet II is
sufﬁcient to form signiﬁcant electrostatic interactions with
certain chemokines. Support for this model comes from an
analysis of the amino acid sequence of those chemokines that
bind A41 most tightly, which reveals that they possess
insertions around the 20s and 40s loops (Figure 5E), with
longer loops conferring greater afﬁnity for A41 (Table 2).
Discussion
This paper provides a structural and functional character-
isation of the VACV A41 protein. This protein was reported
previously to be secreted from VACV-infected cells and to
affect virus virulence [19] and the immune response to
infection [20]. Although the A41 protein shares amino acid
similarity with the family of poxvirus chemokine binding
proteins (vCCI), hitherto its ligand(s) and mechanism of
action were unknown. Here we demonstrate that A41 binds a
subset of CC chemokines (CCL21, 25, 26 and 28) but the
afﬁnity of A41 for these chemokines is 1–3 orders of
magnitude lower than the afﬁnity of VACV protein vCCI
for a wide range of CC chemokines. Consequently, A41
cannot disrupt the high afﬁnity interactions of chemokines
with their cellular receptors and so is unable to inhibit
leukocyte chemotaxis in response to these chemokines.
However, the afﬁnity of A41 for these CC chemokines is still
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high enough to predict that A41 will block the interaction of
chemokines with GAGs, and consistent with this, high
concentrations of GAGs such as heparin and dextran
sulphate disrupted the A41-chemokine interaction. Direct
attempts to block the interaction of hCCL28 and heparin,
immobilised on the surface of BIACORE chips, with excess
A41 achieved a 40% inhibition at 250 nM (data not shown).
These experiments are complicated by the large number of
binding sites present on heparin (mol mass 15,000 Daltons).
These observations suggest that A41 functions by blocking
the interaction of CC chemokines with GAGs on the
endothelial cell surface and thereby disrupting the establish-
ment of a chemokine concentration gradient around the site
of infection. So, in the presence of A41, CC chemokines can
still bind to their receptors on leukocytes and activate these
cells, but the leukocytes would not home to the site of
infection. This model (Figure 6C) ﬁts well with the observed
increased inﬁltration of leukocytes into dermal tissue
infected with a VACV strain engineered to lack the A41L
gene [19] and is similar to the proposed mode of action of the
MYXV M-T7 protein [15]. It also ﬁts well with observations
made with mutant chemokines, such as CCL5, that are
deﬁcient in GAG binding. Despite binding and activating
chemokine receptors in vitro, these chemokines were unable
to recruit cells in vivo, highlighting the importance of GAG
binding to form haptotactic gradients for cells to follow [30].
The structure of the A41 protein was solved to 1.9 A˚
resolution and shows considerable similarity to the family of
chemokine binding proteins (vCCI) from poxviruses, even
though these proteins share only ;19% sequence identity
with A41. Like the CPXV, ECTV and RPXV vCCI proteins
[16–18], A41 is composed of a b sandwich comprising two
parallel b sheets connected and partially covered by extended
loops. Four disulphide bonds contribute to the protein
stability. The extended loops of A41 differ signiﬁcantly from
other vCCI family proteins and these changes are likely to
affect the afﬁnity and speciﬁcity of the chemokines bound. A
notable difference between A41 and other vCCI proteins is
the absence of the 2–4 loop (acidic b strand 3, numbered
according to [16]), which in the RPXV vCCI-CCL4 complex
helps to lock the chemokine in place via electrostatic
interactions [17]. The absence of this loop in A41 may
explain its reduced afﬁnity for chemokines. However, this
apart, the basic interaction of vCCI-CCL4 and the modelled
A41-CCL26 interaction is remarkably similar. As for vCCI-
CCL4, the predicted binding of A41 with CCL26 is aided by
the packing of conserved hydrophobic residues in the N-
terminal loop of the chemokine in a hydrophobic depression
on the A41 surface. This depression is formed primarily by
F181, which is strictly conserved in A41 and in vCCI proteins
from all sequenced orthopoxviruses. The selectivity of A41
for CCL21, 25, 26 and 28 is likely to be inﬂuenced by the lack
of the 2–4 loop in A41 and by the insertion of residues in the
20s and 40s loops of these chemokines (Figure 5E).
The nature of the chemokines bound by A41 also provides
an explanation for the increased immunogenicity of VACV
strains engineered to lack the A41L gene, and in particular
the induction of enhanced levels of antigen speciﬁc CD8þ T
cells in the secondary lymphoid organs [20]. CCL21 is a
pivotal molecule for priming T-cell responses, co-stimulating
the expansion of naı¨ve CD4þ and CD8þ T cells and inducing
Th1 polarization [31]. It recruits CCR7þ T cells and DCs into
the lymph nodes [32] and is responsible for the movement of
CD4þ T cells within the lymph node [33,34]. CCL21 is up-
regulated during a febrile response, promoting uptake of
lymphocytes into the lymph nodes across the high endothelial
venules [35]. This involvement in the formation and main-
tenance of a speciﬁc anti-viral immune response means that
CCL21 is a logical target of many viral proteins. Notably,
Figure 3. The Structure of VACV Protein A41
(A) Cartoon representation of A41 in stereo view, coloured from blue at the N terminus to red at the C terminus, with the four disulphide bonds shown
as yellow sticks. (B) View at 908 to (A), showing the 9–11 loop in yellow. (C) Superposition of A41 and CPXV vCCI in stereo view, with A41 coloured blue
and CPXV vCCI coloured green. (D) CPXV vCCI in the same orientation as (B), with the 2–4 loop coloured green and the 9–11 loop coloured yellow. (E)
Structure-based sequence alignment between VACV A41 and the vCCIs of CPXV, RPXV and ECTV. Structurally equivalent residues defined by SHP [28]
were used to generate a clustalw alignment using shp2clustalw (unpublished program). Identical residues are boxed in blue, and conserved residues
are boxed in white. The secondary structure of A41 is shown above the alignment. The 2–4 loop insertion in the vCCIs, which is absent in A41, is
highlighted in green, and the 9–11 loop in yellow. With the exception of these loops, residues for the vCCIs that are not matched by A41 are omitted
and the position and number of residues removed is indicated under the alignment. This figure was generated with ESPript [64]. PDB IDs 1CQ3, 2FFK
and 2GRK were used for the CPXV vCCI, RPXV vCCI, and ECTV EVM1 proteins, respectively. All molecular representations were generated in PyMOL [65].
doi:10.1371/journal.ppat.0040005.g003
Figure 4. Electrostatic Potential Surfaces of (A) A41 and (B) vCCI
The left hand panels show the molecules as viewed in Figure 5A and 5C.
The right hand panels show the molecules rotated by 1808. Surface
charge was calculated using APBS [66]. Positive charge is coloured blue
and negative charge is coloured red.
doi:10.1371/journal.ppat.0040005.g004
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simian and human immunodeﬁciency viruses [36], hepatitis C
virus [37] and murine c-herpesvirus 68 [38] have evolved
different ways to block its activity.
CCL25 is also involved in the formation of a T-cell
response, although its expression is mainly localised in the
thymus and small intestine. It is responsible for the homing of
CCR9-expressing T-cell progenitors to, and their migration
through, the thymus [39,40]. It is also important for the
development of immune responses in the gut mucosa. CCL28
is also expressed by the mucosal epithelia of the gut, where it
attracts CD4þ and CD8þ resting T cells [41] and has broad
antimicrobial properties [42]. An impairment of its effector
functions by A41 would be expected to affect the T-cell
response, but probably in the mucosa rather than the
lymphoid organs.
It is interesting that VACV encodes two soluble proteins
that bind CC chemokines (vCCI and A41). Of these, A41 is the
more conserved and is expressed by every VACV strain tested
[19] and indeed every sequenced orthopoxvirus species and
strain [9], now more than 75 viruses. In contrast, vCCI is
expressed by only nine out of 15 VACV strains tested [13].
However, each protein can inﬂuence virus virulence: deletion
of gene A41L from VACV strain WR, which does not express
vCCI [13], caused enhanced cellular inﬁltration and reduced
Figure 5. Analysis of Human Chemokines Binding to A41 and Modelling of the A41:CCL26 Complex
The structure of CCL4 (A) coloured green, and the N-terminal loop, 20s loop, and 40s loop are coloured yellow, blue and magenta, respectively. (B) The
NMR complex of CCL4 with the RPXV: vCCI is shown with CCL4 depicted as in (A) and RPXV vCCI is shown with its electrostatic surface charge. The
position of the 2–4 loop is labelled and highlighted by a grey oval. The views are orientated facing the vCCI b sheet II (1808 to the view in Figure 3A). (C)
The structure of CCL26 coloured as (A). The positions of insertions present in the 20s and 409s loops of the CC chemokines that bind to A41 are shown
with spheres coloured blue and magenta, respectively. (D) A model of the interaction between A41 and CCL26 generated using SHP [28], in an
equivalent representation and view to (B). (E) Sequence alignment of CC chemokines that bind to A41 and to vCCIs, created using CLUSTALW [67]. CC
chemokines that bind to A41 are ordered in descending order of affinity to A41E. coli. Those CC chemokines that do not bind to A41, but bind to vCCIs
are shaded grey. The secondary structure of CCL26 is shown above the alignment. Sequence numbering is according to the CCL26 sequence.
doi:10.1371/journal.ppat.0040005.g005
Figure 6. Model of the Interaction of A41 with CCL26, and Schematic Representation of the Biological Mechanism
(A) The model of A41 interaction with CCL26 is shown orientated as in Figure 5D, with the structure based sequence conservation between A41 and
vCCIs mapped onto the A41 surface (coloured as in Figure 3E, with dark blue patches representing strict sequence identity, the colour scheme for
CCL26 is as for Figure 5A). (B) A close up of the interaction between the N-terminal loop of CCL26 and the Phe181 of A41. The A41 surface is shown
semitransparent with a cartoon representation of A41 in pale green beneath the surface. (C) Model for mode of action of vCCI-like proteins and A41.
The epitope for chemokine receptor on the chemokine is shown in yellow whilst the portion of the chemokine surface that interacts with GAG is
coloured blue.
doi:10.1371/journal.ppat.0040005.g006
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virulence in rabbit skin [19]; conversely, insertion of the vCCI
gene from VACV strain Lister into VACV strain WR, which
expresses A41, attenuated the virus in a murine intranasal
model, characterized by reduced mortality and weight loss,
decreased virus replication and spread, and a reduced
recruitment of inﬂammatory cells into the lungs [43]. These
proteins therefore have distinct roles, consistent with their
different binding speciﬁcities, afﬁnities and modes of action.
In the light of the results for A41 we can reformulate the
model whereby vCCI-like molecules block the chemokine
receptor epitope, whilst A41 or MT-7-like molecules block
the GAG binding epitope of the chemokines. In our revised
model (Figure 6C) the binding sites on chemokines for GAGs
and chemokine receptors largely overlap and the functional
distinction between the two classes of molecules arises simply
from the differences in binding afﬁnity. vCCI binds sufﬁ-
ciently tightly to block the interaction of chemokines with
their receptors and GAG binding is also blocked. In contrast,
A41 acts by blocking the establishment of a chemokine
concentration gradient by competing with GAG binding only.
Having both strategies may be advantageous for a virus
because some chemokines, such as CCL21, can exert some of
their functions without forming concentration gradients (a
process known as chemokinesis) [44]. This ability, coupled
with the anti-viral potency of CCL21, may mean that some
viruses have evolved more than one way to target this
chemokine and inhibit its various functions.
Materials and Methods
Expression of A41 in the VOTE system. The VACV strain Western
Reserve (WR) A41L gene was ampliﬁed from plasmid pA41 [19] by
PCR using primers GGGGATTAATATGTACTCGTTAGTATTTG
and GGGGGAATTCTTAACAATTATCAAATTTTTTC. The DNA
was digested with AseI and EcoRI and ligated into plasmid pVOTE2
[22] that had been digested with NdeI and EcoRI. The sequence of the
A41L open reading frame within the resultant plasmid pVOTE2-A41
was veriﬁed by DNA sequencing. Virus VOTE-A41 was constructed by
transfection of pVOTE2-A41 into RK13 cells infected with virus
vT7lacOI [22], and selection of recombinant virus using methodology
described previously [22].
Puriﬁcation of A41 from mammalian cells. To express A41 in
mammalian cells, monolayers of RK13 cells were infected with VOTE-
A41 at 5 p.f.u. / cell for 90 min, washed and then incubated in culture
medium containing 3 mM IPTG and 190 mM NaCl. At 24 h p.i. A41
was puriﬁed from the culture medium. The medium was concen-
trated ;50-fold using centrifugal concentrators with a 10 kDa cut-off
(Amicon). Virus particles were inactivated by treatment with 20 lg/
mL psoralen and long-wave UV for 20 min on ice [45] and removed
by ultracentrifugation (80 min, 35,000 x g). The supernatant was then
applied to a 20 ml Resource Q column (GE Healthcare) pre-
equilibrated with 2 column volumes of TE (50 mM Tris-HCl pH 7.0,
1 mM EDTA) containing 50 mM NaCl. Unbound proteins were
washed out with two column volumes of low salt (50 mM NaCl) TE
buffer, and bound proteins were then eluted with a salt gradient (50 –
400 mM NaCl). The protein content of each fraction was analysed by
SDS-PAGE, Coomassie blue staining and immunoblotting with anti-
A41 antibody [19]. Fractions containing the A41 protein peak were
pooled and concentrated to 200 ll using a 2 ml centricon (Amicon).
The concentrated samples were then puriﬁed further by SEC on a
Superdex S75 HR 10/30 column in PBS. Fractions containing A41
were pooled and concentrated to 200 ll using a 2 ml centricon
(Amicon). SDS-PAGE showed a single 30 kDa protein that reacted
with the anti-A41 antibody by immunoblotting.
Surface plasmon resonance (BIACORE). The carboxymethylated
dextran surface of a CM5 sensor chip (GE Healthcare) was activated
with 50 mM N-hydroxysuccinimide (NHS) and 200 mM N-ethyl-N9-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC). Proteins
A41 and ovalbumin in 10 mM sodium acetate pH 4 were then coupled
to different ﬂowcells on the chip at a rate of 5 lL/min using the
BIACORE Application Wizard to a target of 1000 response units (RU)
for the binding experiments. The chip surface was then deactivated
and unbound protein was removed by injecting a pulse of 1 M
ethanolamine hydrochloride pH 8.5 across all ﬂowcells. To perform
screening for analyte binding, the murine chemokines CCL1, CCL2,
CCL4, CCL6, CCL7, CCL8, CCL9/10, CCL11, CCL12, CCL19, CCL20,
CCL21, CCL22, CCL24, CCL27, CCL28, CXCL2, CXCL5, CXCL9,
CXCL10, CXCL11, CXCL12a, CXCL12b, CXCL13, XCL1, CX3CL1,
and the human chemokines CCL14, CCL15, CCL16, CCL17, CCL18,
CCL23, CCL25, CCL26, CXCL3, CXCL4, CXCL6 and CXCL7
(Peprotech Ec) were passed over the chip surface sequentially, at 50
nM (25 lL/min, 2 min injection) in HBS-EP buffer (10 mM Hepes pH
7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20). The surface
of the chip was regenerated in between each analyte with 10 mM
glycine pH 3. The value observed from the empty ﬂowcell (Fc1) was
deducted electronically from the other ﬂowcells. For kinetic analyses
of A41 binding, a target of 250 RU of puriﬁed A41VOTE and A41E.coli
was coupled to the surface of a new CM5 sensor chip. Various
concentrations (3.125 nM – 50 nM) of each chemokine in HBS-EP
were passed over the chip (50 ll/min, 2 min injection). To calculate
the dissociation constant (Kd) for each analyte, data were analysed
using a simultaneous ka/kd ﬁtting procedure and a Langmuir (1:1)
model. The quality of the ﬁt was assessed using the residuals plot and
the v2 value.
To investigate if GAGs inhibited the binding of A41 and chemo-
kines, a new chip was prepared by immobilising 1000 RU of puriﬁed
A41VOTE and A41E.coli as described above for the binding assays.
Chemokines were incubated at room temperature for 1 h in the
presence of increasing concentrations (0, 31.25, 62.5, 125, 250, 500 ng/
ml) of heparin sodium salt (low molecular weight, MW 4,000–6,000,
Sigma-Aldrich) or various other sulphated GAGs (125 or 250 ng/ml
heparan sulphate sodium salt, chondroitin sulphate B sodium salt
(¼dermatan), chondroitin 6-sulphate sodium salt (¼chondroitin
sulphate C), hyaluronic acid and dextran sulphate, all Sigma-Aldrich)
and BIACORE analysis performed as above.
Chemotaxis assays. Assays were performed as described previously
[46]. Brieﬂy, different concentrations of A41 or Ova were incubated
with mouse (m) or human (h) CCL21, CCL25 or CCL28 or human
CCL26, in 31 ll in the bottom well of 96-well ChemoTxTM plates
(Receptor Technologies, Oxford, UK). Five to 8 samples were
analysed for each concentration. A 5 lm ﬁlter was placed onto the
wells and 23105 target cells in 20 ll were placed onto the ﬁlter above
each well. Plates were incubated for 5 h at 37 8C and cells that had
migrated through the membrane were counted with a haemocytom-
eter. Target cells were mouse L1.2 cells that express CCR7 naturally
(used for mCCL21 and hCCL21) [47], 4DE4 cells expressing CCR3
(used for CCL26) [25] and L1.2 cells transfected transiently with
plasmids expressing wild type or N-terminally HA-tagged human
CCR9 and CCR10 (http://www.cdna.org/) as described [48]. The
surface expression of HA was veriﬁed before each experiment by
FACS analysis, as described [49], using a monoclonal anti-HA
antibody (Covance) at 1/100 dilution, and FITC-conjugated goat
anti-mouse at 1/20 dilution (Dako) and the appropriate isotype
control (Sigma-Aldrich). Initial experiments were performed using
wild type and HA tagged alleles to ensure that the HA tag did not
interfere with receptor function. To determine the concentration of
each chemokine that induced the optimal chemotaxis, chemokine
concentrations between 5 and 150 nM were tested. Concentrations
used were 10 nM for hCCL21 and mCCL21, 20 nM for mCCL25, 50
nM for hCCL25, 40 nM for CCL26, 100 nM for mCCL28 and 60 nM
for hCCL28.
Cloning and expression of Escherichia coli A41. The A41L gene
(encoding residues 21–219, excluding the secretion signal) was
ampliﬁed by PCR from VACV strain WR DNA with KOD Hot Start
DNA polymerase (Novagen) using forward primer 59-ggggacaagtttgta-
caaaaaagcaggcttcgaaggagatagaaccatggcacatcaccaccaccatcacGATGA-
TAAATCGGTATGCGATTC-39 and reverse primer 59-ggggaccactttg
tacaagaaagctgggtctcaTTAACAATTATCAAATTTTTTCTTTAA-
TATTTTACG-39. The forward primer encoded a start codon and an
N-terminal His6 tag. Both primers featured the attB site of the gateway
cloning system (Invitrogen) that was used to subclone the puriﬁed PCR
product into the pDEST14 expression vector. The expression plasmid
was shown to be mutation free by sequencing.
Native A41 was expressed in the E. coli strain Rosetta(DE3)pLysS.
Cultures were grown at 37 8C for 4 h in GS96 medium (Invitrogen),
supplemented with Overnight Express Autoinduction System 1
(Novagen), before being incubated at 25 8C overnight. Selenomethio-
nine (SeMet) labelled protein was expressed in the E. coli methionine
auxotrophic strain B834(DE3) (Novagen). Cells were cultured at 37 8C
in SeMet medium (Molecular Dimensions Ltd.) supplemented with 40
mg/l SeMet, until the OD595 reached 0.6. Cultures were then cooled to
PLoS Pathogens | www.plospathogens.org January 2008 | Volume 4 | Issue 1 | e50066
Structure and Function of Vaccinia Virus A41
20 8C, A41 expression was induced by addition of 0.5 mM Isopropyl-
bD-thiogalactopyranoside and the culture was left to incubate
overnight. All cultures were harvested by centrifugation (6000 3 g,
4 8C, 20 min) and stored at 80 8C until use.
Refolding and puriﬁcation. Cell pellets were resuspended in
phosphate-buffered saline (PBS) with 0.5 % (v/v) Tween-20, and lysis
was performed by sonication (Sonics Vibracell) on ice. Inclusion
bodies, comprising mainly A41, were isolated by centrifugation
(30,000 x g, 8 8C, 10 min) and subjected to several washes in triton
wash buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, and 0.5 % (v/v)
triton X-100) with centrifugation (as above) between washes to re-
collect inclusion bodies. A ﬁnal wash was performed in detergent free
buffer (50 mM Tris-HCl pH 8.0 and 100 mM NaCl). The inclusion
bodies were then dissolved overnight at 4 8C in a denaturing buffer
containing 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 6 M guanidine
hydrochloride and 10 mM DTT, followed by centrifugation (30,0003
g, 8 8C, 30 min) to remove undissolved waste. The supernatants
containing denatured A41 were stored at20 8C before refolding by
rapid dilution with stirring of 20 mg of denatured inclusion bodies
into 200 ml of refolding buffer containing 200 mM Tris-HCl pH 8.0, 1
M L-Arginine, 6.5 mM cysteamine, 3.7 mM cystamine, plus 1 EDTA-
free protease inhibitor cocktail tablet (Roche). Refolding reactions
were incubated at 4 8C for between 24–48 h, followed by concen-
tration to a volume of 5 ml in a vivacell 250 concentrator
(Vivascience) with a 10 kDa cut-off. Concentrated protein was
puriﬁed by SEC on a HiLoad 16/60 Superdex 200 column (GE
Healthcare), into a ﬁnal buffer of 20 mM Tris-HCl pH 7.5 and 200
mM NaCl. One hundred percent incorporation of selenomethionine
was conﬁrmed by mass spectrometry.
Crystallization and data collection. Prior to crystallization, puriﬁed
A41 was concentrated by ultraﬁltration to 3 mg/ml in a 10 kDa cut-off
concentrator (Vivascience). For both native and SeMet-substituted
A41, initial vapour diffusion crystallization experiments were
performed at 21 8C in 300 nl drops (protein/precipitant ratio of
2:1) using a Cartesian robot [50,51]. Crystals were grown from a
mother liquor of 0.2 M potassium ﬂuoride, 20 % polyethylene glycol
3350. Based on this result, further optimisations were performed [52].
Crystals of A41 belong to space group P21, (unit cell dimensions a ¼
36.6A˚, b¼ 60.8A˚, c¼ 50.4A˚, b¼ 91.08), and contain one molecule per
asymmetric unit with an estimated solvent content of 50 %. Both
native and SeMet crystals were ﬂash frozen at 100K in mother liquor
containing 20 % glycerol. Diffraction data to 1.9 A˚ resolution were
collected for the native crystals at the European Synchrotron
Radiation Facility (ESRF), beamline ID14 EH1. A multiple wavelength
anomalous diffraction (MAD) analysis was performed at 2.3 A˚
resolution on a SeMet crystal at beamline BM14 at the ESRF. All
oscillation images were processed and reduced using the HKL
software suite [53] (Table 1).
Structure solution and reﬁnement. The structure of A41 was solved
using the MAD method. Each monomer of A41 contains four SeMet
residues and the positions of these were determined using SHELXD
[54] and initial phases computed with SHELXE [55] as part of the
HKL2MAP package [56]. Density modiﬁcation used RESOLVE [57],
and the resulting electron density map was of excellent quality,
allowing an automatic chain trace to be performed with Arp/wARP
[58], which built 160 out of 199 residues. The remainder of the
structure was modelled in the program O [59]. Initial reﬁnement was
performed using program CNS [60]. The 1.9 A˚ native data were
isomorphous to the SeMet data, permitting reﬁnement to be directly
extended to this higher resolution in the program REFMAC [61] with
iterative rebuilding in COOT [62]. For the ﬁnal model the Rwork is
19.4 % and the Rfree is 24.9 % (Table 1). The stereochemical quality of
the structure was assessed using the MOLPROBITY program [63]. The
structure has good stereochemistry with 94.3 % of residues lying in
the most favoured regions of the Ramachandran plot.
Modelling of the CC26-A41 complex. The CC26-A41 complex was
modelled by superimposing A41 onto the vCCI component of the
RPXV vCCI-CCL4 complex (pdb code 2FF3) (159 equivalences with
an rmsd of 2.4A˚), and then superposing CCL26 (pdb code 1G2S) onto
the CCL4 component (59 equivalences with an rmsd of 1.8 A˚). All
superpositions were done automatically using SHP [28].
Supporting Information
Accession Numbers
Coordinates and structure factors have been deposited in the Protein
Data Bank (PDB; http://www.rcsb.org/pdb/) with accession numbers
2vga and 2vgasf.
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